|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.10 GBX | -5.49% |
|
-0.59% | +15.69% |
| 24/02 | Avacta hails new data supporting proprietary preCision platform | AN |
| 24/02 | Avacta Therapeutics Plans FAP-Exd's Clinical Trials After 'Favorable' Experimental Analysis | MT |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 3.06Cr | -216.35% | -133.3% | - | - | 0.49x | |
| 221.87Cr | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 537.62Cr | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 61Cr | -210.54% | -205.59% | -249.28% | - | 0.72x | |
| 284.82Cr | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 255.86Cr | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 369.4Cr | 25.89% | 28.63% | 20.56% | 12.29% | -1.54x | |
| 29Cr | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 26Cr | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 232.01Cr | 33.73% | 37.59% | 35.53% | 27.02% | -1.18x | |
| 96Cr | -30.08% | -31.31% | -42.49% | - | 2.15x | |
| 11Cr | -310.18% | -226% | - | - | - | |
| 83Cr | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 50Cr | 32.27% | 31.52% | 16.33% | 13.74% | -4x | |
| 8.8Cr | -891.6% | -695.44% | - | -54.35% | 0.77x | |
| 178.61Cr | 6.64% | 9.69% | 4.89% | 1.76% | 4.17x | |
| Average | 153.01Cr | -96.47% | -74.98% | -15.85% | 0.59% | 55.84x | |
| Weighted average by Cap. | 222.53Cr | -52.1% | -49.11% | -26.88% | 3.52% | 145.09x |
- Stock Market
- Equities
- AVCT Stock
- Sector Avacta Group Plc
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition